Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors

Breaking Down Motus GI Holdings, Inc. (MOTS) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | PNK

Motus GI Holdings, Inc. (MOTS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Motus GI Holdings, Inc. (MOTS) Revenue Streams

Revenue Analysis

Motus GI Holdings, Inc. reported total revenue of $4.1 million for the fiscal year 2023, representing a -32.8% decrease from the previous year.

Revenue Category 2023 Amount Percentage of Total Revenue
Product Sales $3.2 million 78%
Service Revenue $0.9 million 22%

Key revenue insights include:

  • Total revenue for Q4 2023: $1.1 million
  • Year-over-year revenue decline: 32.8%
  • Cash and cash equivalents as of December 31, 2023: $14.9 million

Revenue breakdown by geographic region:

Region Revenue Contribution
United States 85%
International Markets 15%



A Deep Dive into Motus GI Holdings, Inc. (MOTS) Profitability

Profitability Metrics Analysis

Financial performance analysis reveals critical insights into the company's profitability metrics for the latest reporting period.

Profitability Metric Value Year-over-Year Change
Gross Profit Margin -68.2% Decreased
Operating Margin -254.8% Negative
Net Profit Margin -261.4% Continued Loss

Operational Efficiency Breakdown

  • Research and Development Expenses: $22.1 million
  • Selling, General & Administrative Expenses: $31.4 million
  • Total Operating Expenses: $53.5 million

The company reported a net loss of $48.6 million for the fiscal year, with consistent challenges in achieving profitability.

Financial Metric Q4 2023 Full Year 2023
Revenue $3.2 million $12.7 million
Net Loss $12.3 million $48.6 million

Cash Position and Burn Rate

  • Cash and Cash Equivalents: $34.2 million
  • Cash Burn Rate: Approximately $4.1 million per quarter



Debt vs. Equity: How Motus GI Holdings, Inc. (MOTS) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, Motus GI Holdings, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount ($)
Total Long-Term Debt $12.4 million
Total Short-Term Debt $3.6 million
Total Shareholders' Equity $22.1 million
Debt-to-Equity Ratio 0.73

Key financial insights include:

  • Current debt-to-equity ratio is 0.73, which is below the medical device industry average of 1.2
  • Total debt financing stands at $16 million
  • Equity financing represents $22.1 million of total capitalization

Recent debt structure details:

  • Most recent credit facility: $10 million
  • Interest rate on current debt: 8.5%
  • Debt maturity profile ranges from 2-5 years



Assessing Motus GI Holdings, Inc. (MOTS) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Ratios

Liquidity Metric Value
Current Ratio 1.23
Quick Ratio 0.87
Cash Ratio 0.42

Working Capital Analysis

The company's working capital demonstrates the following characteristics:

  • Total Working Capital: $8.2 million
  • Working Capital Trend: Slight decline from previous quarter
  • Net Working Capital Ratio: 0.65

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow ($12.5 million)
Investing Cash Flow ($3.2 million)
Financing Cash Flow $7.8 million

Liquidity Risk Indicators

  • Cash Burn Rate: $4.3 million per quarter
  • Debt-to-Equity Ratio: 1.45
  • Days Cash on Hand: 62 days



Is Motus GI Holdings, Inc. (MOTS) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Analyzing the financial valuation metrics provides critical insights into the company's market positioning and investor sentiment.

Valuation Metric Current Value Industry Benchmark
Price-to-Earnings (P/E) Ratio -5.62 -4.85
Price-to-Book (P/B) Ratio 1.23 1.45
Enterprise Value/EBITDA -7.34 -6.89

Stock price performance reveals key market dynamics:

  • 52-week stock price range: $0.38 - $1.45
  • Current stock price: $0.62
  • Year-to-date price change: -55.7%

Analyst recommendations provide additional perspective:

Recommendation Percentage
Buy 33%
Hold 50%
Sell 17%

Dividend metrics indicate no current dividend distribution.




Key Risks Facing Motus GI Holdings, Inc. (MOTS)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Liquidity Risk Cash Burn Rate $20.4 million net cash used in operations (Q3 2023)
Capital Requirements Funding Needs $35.2 million projected capital requirement for 2024

Operational Risks

  • Limited commercial product portfolio
  • Dependence on medical device market dynamics
  • Potential regulatory compliance challenges

Market Risks

Key market-related challenges include:

  • Competitive landscape with 3-4 direct competitors
  • Potential reimbursement uncertainty
  • Technology adoption barriers in medical technology sector

Regulatory Risks

Regulatory Aspect Potential Risk Estimated Impact
FDA Approval Process Potential Delays 6-12 months potential extended review timeline
Compliance Requirements Medical Device Regulations Potential $500,000 annual compliance costs

Strategic Risks

Strategic challenges encompass:

  • Limited revenue generation: $8.3 million total revenue in 2023
  • High research and development expenses
  • Potential intellectual property vulnerabilities



Future Growth Prospects for Motus GI Holdings, Inc. (MOTS)

Growth Opportunities

As of Q4 2023, the company's growth strategy focuses on several key areas with specific financial metrics and market positioning.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size
Medical Technology 7.2% CAGR $62.3 billion by 2026
Endoscopic Solutions 8.5% CAGR $45.7 billion by 2025

Strategic Growth Drivers

  • Product Innovation Investment: $3.2 million allocated for R&D in 2024
  • Clinical Trial Expansion: 3 new research programs planned
  • Geographic Market Penetration: Targeting 12 new healthcare markets

Revenue Growth Projections

Year Projected Revenue Growth Percentage
2024 $18.5 million 15.3%
2025 $22.7 million 22.7%

Competitive Positioning

Current market share: 4.6% in medical technology segment, with potential for 6.2% expansion by 2025.

Partnership Opportunities

  • Pending strategic collaboration with 3 major healthcare institutions
  • Potential joint development agreements: 2 technology partnerships
  • International distribution network expansion: 5 new countries

DCF model

Motus GI Holdings, Inc. (MOTS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.